First patient dosed

Weight-loss drugs usually work by telling the brain and gut that a meal was bigger than it was. MetaVia’s drug candidate DA-1726 adds a second signal that tries to make the body burn more fuel at the same time. (clinicaltrials.gov) (thelancet.com) That first signal is glucagon-like peptide-1, a gut hormone released after eating that slows stomach emptying and cuts appetite. Drugs that copy glucagon-like peptide-1 became the foundation of the current obesity market because they can lower food intake week after week. (amjmed.com) (thelancet.com) The second signal is glucagon, a hormone better known for raising blood sugar, but drug developers use it here for another reason: it can push energy expenditure higher, like turning up a thermostat so the body burns a little more while resting. That extra burn is why companies keep testing dual glucagon-like peptide-1 and glucagon drugs even though glucagon has to be balanced carefully. (academic.oup.com) (sciencedirect.com) DA-1726 is built to hit both receptors with one weekly shot, and MetaVia describes it as an oxyntomodulin analog, meaning it is designed to mimic a natural gut hormone that already talks to both pathways. The company is testing it in adults ages 18 to 65 with body mass index between 30 and 45. (sec.gov) (clinicaltrials.gov) The news on April 10, 2026 was not an approval or late-stage win. It was the first patient entering Part 3 of a Phase 1 study, which is the stage where a company is still asking basic questions about safety, side effects, drug levels in the blood, and how fast it can raise the dose. (sec.gov) (clinicaltrials.gov) Part 3 is where MetaVia starts pushing higher. The company said this section has two 16-week groups: one goes from 16 milligrams for 4 weeks to 48 milligrams for 12 weeks, and the other goes from 16 milligrams to 32 milligrams to 64 milligrams over the same 16 weeks. (prnewswire.com) (sec.gov) That step-up plan is called titration, and it is the obesity-drug version of easing into cold water instead of jumping straight in. Companies use titration because nausea, vomiting, and other stomach side effects often get worse when dose increases happen too fast. (prnewswire.com) (clinicaltrials.gov) MetaVia is trying to show DA-1726 can climb faster than some marketed drugs without losing tolerability. The company said Part 3 will enroll 40 adults, split into two groups of 20, with each group randomized 4-to-1 so 16 people get DA-1726 and 4 get placebo. (prnewswire.com) (sec.gov) The reason investors were watching this small Phase 1 study before Part 3 is that earlier cohorts already showed unusually large early weight loss for such an early program. MetaVia reported up to 6.3% maximum weight reduction and a mean 4.3% reduction by Day 26 at 32 milligrams in a 28-day multiple-dose cohort. (prnewswire.com) The company later extended a 48 milligram cohort to 8 weeks and said average weight loss reached about 9.1% by Day 54. In the April 10, 2026 announcement, MetaVia also said it saw reductions in waist circumference, better glycemic control, and early signals of liver benefit. (fiercebiotech.com) (prnewswire.com) Those numbers are still coming from small, early cohorts, and Phase 1 studies are not built to prove that a drug will win in the real market. MetaVia said data from this higher-dose Part 3 section are expected in the fourth quarter of 2026, so the next real test is whether 48 to 64 milligrams can keep the weight-loss signal while staying tolerable over 16 weeks. (prnewswire.com) (sec.gov)